Yingli Pharma

Yingli Pharma, a US-based biopharmaceutical company focused on developing therapies for both the Chinese and American markets, has announced the enrollment of its first patient in a Phase I clinical study for YL-17231, a novel pan-KRAS inhibitor targeting malignant solid tumors, at the MD Anderson Cancer Center. This milestone follows…